Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.72 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.72 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.72 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095607 | 1.00 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6094761 | 0.90 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6094767 | 0.90 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6817357 | 0.90 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6817158 | 0.89 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6821214 | 0.88 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6812883 | 0.88 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL6651799 | 0.88 | MAPK14 (0.84) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL6813046 | 0.88 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6098679 | 0.87 | MAPK13 (0.66) | MAPK14MAPK13MAPK12MAPK11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210320-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | claimed |
| US-6566554-B1 | Including amino benzothiophenones; useful for treatment of inflammatory diseases in which the production of cytokines is involved in the pathogenesis | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2003-05-20 | — | — | US | claimed |
| CN-100347151-C | Novel aminobenzophenones | LEO PHARMA AS (DK) | 2007-11-07 | — | — | CN | disclosed |
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| CN-1561327-A | Novel aminobenzophenones | LEO PHARMA AS (DK) | 2005-01-05 | — | — | CN | disclosed |
| EP-1210320-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | disclosed |
| EP-1423356-A2 | NOVEL AMINOBENZOEPHENONES | Leo Pharma A/S (DK) | 2004-06-02 | — | — | EP | disclosed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | disclosed |
| US-6566554-B1 | Including amino benzothiophenones; useful for treatment of inflammatory diseases in which the production of cytokines is involved in the pathogenesis | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2003-05-20 | — | — | US | disclosed |
| WO-2003018535-A2 | NOVEL AMINOBENZOEPHENONES | LEO PHARMA A/S (DK) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | IL1B, IL1A, TNF | MAPK14 1972/4885MAPK13 2918/4885MAPK12 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.